InSilicoTrials Revenue (2024)

Luca Emili

CEO

I am a serial entrepreneur. With a background in the cybersecurity and IT-cloud sectors, a few years ago, decided to invest in healthcare by purchasing a small digital CRO (Contract Research Organization). I saw that pharma and Medtech were facing the same problems I had already solved in my career, so I founded InSilicoTrials Technologies and made it my mission to help the industry digitalize R&D and deliver better and safer cures, in a shorter timeframe, while saving money. To do that, I built close relationships with regulatory bodies, companies and associations like the Avicenna Alliance, where I lead the Good Simulation Practice for healthcare initiative. I believe that the healthcare industry is at a pivotal crossroad. We all know that R&D costs are rising year over year and became unsustainable for most of the players, putting innovation at risk. On top of that, the long certification/registration process is eroding the time on the market for which these costs can be recovered. In the meanwhile, patients desperately need better cures. Digitalization is seen as a possible solution, that already worked in other safety-critical industries, but the implementation is a huge challenge to face. I’ve built a team with a unique mix of competencies in computational science, drugs development, engineering, regulatory approval, and IT to put together a unique solution with a goal: De-risk and accelerate R&D and regulatory approval of medicines and medical devices through a game-changing approach to modeling and simulation. InSilicoTrials Technology makes it easy for scientists, researchers, and doctors to use the incredible knowledge developed in universities and research centers all over the world by collecting them on a web-based platform. Now there is a single stop point to use them, and our technology is making it so simple that they don’t need to be simulation experts to do it, but they can learn in a matter of minutes.